RecruitingPhase 2NCT07147049

Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery

Sponsor

Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

Enrollment

72 participants

Start Date

Aug 8, 2025

Study Type

INTERVENTIONAL

Conditions

Moderate to Severe Acute Postoperative Pain

Summary

This is a multiple-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and pharmacokinetics (PK) parameter of HL-1186 tablet for moderate to severe acute pain after surgery.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HL-1186 and a drug called HL-1186 placebo for people with moderate to severe acute postoperative pain. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHL-1186

HL-1186 tablet for oral administration.

DRUGHL-1186 placebo

HL-1186 placebo tablet for oral administration.

Locations(1)

Sichuan Provincial People's Hospital

Chengdu, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07147049

Related Trials

Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Pain Management in Abdominal Surgery

NCT073113691 location